You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project—Part 2)
|
|---|---|
| Published in |
Journal of Thoracic Oncology, October 2012
|
| DOI | 10.1097/jto.0b013e318265b2b5 |
| Pubmed ID | |
| Authors |
Jacques Cadranel, Audrey Mauguen, Michele Faller, Gérard Zalcman, Marie-Pierre Buisine, Virginie Westeel, Elisabeth Longchampt, Marie Wislez, Bruno Coudert, Catherine Daniel, Bruno Chetaille, Stephane Michiels, Helene Blons, Jerome Solassol, Florence De Fraipont, Pascal Foucher, Thierry Urban, Ludovic Lacroix, Virginie Poulot, Elisabeth Quoix, Martine Antoine, Guillaume Danton, Franck Morin, Christos Chouaid, Jean-Pierre Pignon, on behalf of the ERMETIC collaborative group and the Intergroupe Francophone de Cancerologie Thoracique |
| Abstract |
Epidermal growth factor and v-Ki-ras2 Kirsten ras sarcoma (KRAS) mutation status, although associated with EGFR- tyrosine kinase inhibitor (TKI) efficacy, has not been used in clinical practice until recently. The prospective Evaluation of the EGFR Mutation status for the administration of EGFR-TKIs in non small cell lung Carcinoma (ERMETIC) study aimed to implement these biomarkers in France. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 77 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 1% |
| France | 1 | 1% |
| Ireland | 1 | 1% |
| Unknown | 74 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 18% |
| Student > Ph. D. Student | 11 | 14% |
| Student > Master | 10 | 13% |
| Other | 9 | 12% |
| Student > Bachelor | 6 | 8% |
| Other | 16 | 21% |
| Unknown | 11 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 42 | 55% |
| Biochemistry, Genetics and Molecular Biology | 4 | 5% |
| Nursing and Health Professions | 3 | 4% |
| Agricultural and Biological Sciences | 3 | 4% |
| Mathematics | 3 | 4% |
| Other | 10 | 13% |
| Unknown | 12 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 September 2012.
All research outputs
#20,656,820
of 25,374,647 outputs
Outputs from Journal of Thoracic Oncology
#2,612
of 3,511 outputs
Outputs of similar age
#148,864
of 190,995 outputs
Outputs of similar age from Journal of Thoracic Oncology
#44
of 79 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,511 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.3. This one is in the 6th percentile – i.e., 6% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 190,995 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 79 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.